Samuel Joseph Parisi Net Worth

The estimated Net Worth of Samuel Joseph Parisi is at least 281 千$ dollars as of 23 February 2024. Samuel Parisi owns over 2,559 units of Alkermes plc stock worth over 205,041$ and over the last few years Samuel sold ALKS stock worth over 75,874$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Samuel Parisi ALKS stock SEC Form 4 insiders trading

Samuel has made over 3 trades of the Alkermes plc stock since 2024, according to the Form 4 filled with the SEC. Most recently Samuel sold 2,559 units of ALKS stock worth 75,874$ on 23 February 2024.

The largest trade Samuel's ever made was exercising 3,906 units of Alkermes plc stock on 18 February 2024 worth over 103,782$. On average, Samuel trades about 3,193 units every 2 days since 2024. As of 23 February 2024 Samuel still owns at least 7,717 units of Alkermes plc stock.

You can see the complete history of Samuel Parisi stock trades at the bottom of the page.

What's Samuel Parisi's mailing address?

Samuel's mailing address filed with the SEC is 900, Winter Street, Prospectville, Waltham, Middlesex County, Massachusetts, 02451, United States.

Insiders trading at Alkermes plc

Over the last 13 years, insiders at Alkermes plc have traded over 407,046,771$ worth of Alkermes plc stock and bought 86,119 units worth 2,034,840$ . The most active insiders traders include Corp Plc Elan Science Three...、Richard F Pops、James M Frates. On average, Alkermes plc executives and independent directors trade stock every 5 days with the average trade being worth of 1,083,232$. The most recent stock trade was executed by David Joseph Gaffin on 3 August 2024, trading 2,014 units of ALKS stock currently worth 53,512$.

What does Alkermes plc do?

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.

Complete history of Samuel Parisi stock trades at Alkermes plc

Alkermes plc executives and stock owners

Alkermes plc executives and other stock owners filed with the SEC include:

• Richard Pops,
  Chairman of the Board, Chief Executive Officer
• Craig Hopkinson,
  Executive Vice President, Research and Development and Chief Medical Officer
• David Gaffin,
  Senior Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
• James Frates,
  Chief Financial Officer, Senior Vice President
• Michael Landine,
  Senior Vice President - Corporate Development, Chief Risk Officer
• Richard F. Pops,
  Chairman & CEO
• Dr. Craig C. Hopkinson,
  Exec. VP of R&D and Chief Medical Officer
• David Joseph Gaffin,
  Sr. VP, Chief Legal Officer, Chief Compliance Officer & Sec.
• Frank Wilson,
  Independent Director
• Richard Gaynor,
  Independent Director
• Michael J. Landine,
  Sr. VP of Corp. Devel. & Chief Risk Officer
• Paul Mitchell,
  Independent Director
• Robert Breyer,
  Independent Director
• David Anstice,
  Lead Independent Director
• Nancy Snyderman,
  Independent Director
• Wendy Dixon,
  Independent Director
• Nancy Wysenski,
  Independent Director
• Shane Cooke,
  Director
• Iain Brown,
  Senior Vice President - Finance, Chief Accounting Officer
• Peter Norman,
  Sr. VP of Policy & Gov. Relations
• Iain Michael Brown,
  Sr. VP & CFO
• Dr. Floyd E. Bloom M.D.,
  Founder
• Stephen Schiavo,
  Sr. VP of HR
• Eva Stroynowski,
  VP of Product & R&D Communications, Public Affairs
• Sandra Coombs,
  Co-Head of Investor Relations
• Blair C. Jackson,
  Exec. VP & COO
• Dr. Floyd E. Bloom,
  Founder
• Floyd E Bloom,
  Director
• Elliot Ehrich,
  SVP, R&D & CMO, Alkermes, Inc.
• Mark Stejbach,
  Chief Commercial Officer
• James A. Jr. Robinson,
  President & COO,Alkermes, Inc.
• Nancy Lurker,
  Director
• Rebecca Peterson,
  SVP, Corporate Communications
• Geraldine Henwood,
  Director
• Kathryn L Biberstein,
  SVP, GC, Secretary, Alks, Inc.
• Gordon G Pugh,
  SVP, COO & CRO, Alkermes, Inc.
• James L Botkin,
  SVP, Alkermes Gainesville LLC
• Mark B Skaletsky,
  Director
• Corp Plc Elan Science Three...,
  
• Christian Todd Nichols,
  SVP, Chief Commercial Officer
• Brian P Mckeon,
  Director
• David Angelo Jr. Daglio,
  Director
• Blair Curtis Jackson,
  EVP, Chief Operating Officer
• Emily Peterson Alva,
  Director
• Cato T Laurencin,
  Director
• Christopher I Wright,
  Director
• Samuel Joseph Parisi,
  VP, Finance (Interim PAO)